±³À°ÀÏÁ¤

Çѱ¹ÀÀ¿ë¾à¹°ÇÐȸ ½Å¾à°³¹ßÀü¹®°¡ ¾ç¼º ±³À° ÇÁ·Î±×·¥: ±âº»°úÁ¤

»çȸ: ±è¼ÒÈñ ±³¼ö (¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ)

Time Program
09:30- ±³À°ÇÁ·Î±×·¥ Á¢¼Ó
10:00-10:10 Opening Remark
Greeting from President of KSAP
Session 1: ¾àÈ¿ ¹× ¾ÈÀü¼º Æò°¡ÀÇ ÀÌÇØ
10:10-10:55
½Å¾à °³¹ß¿¡¼­ Ç×¾ÏÁ¦ÀÇ À¯È¿¼º Æò°¡
Evaluating Efficacy of Anti-cancer Agents in Drug Development
¢º ±è¿ì¼÷ ¹Ú»ç / LGÈ­ÇÐ »ý¸í°úÇлç¾÷º»ºÎ ½Å¾à¿¬±¸¼Ò
10:55-11:10 Q & A
11:10-11:55
Èĺ¸¹°Áú ÃÖÀûÈ­ ´Ü°è¿¡¼­ÀÇ ºñÀÓ»ó °í·Á»çÇ×
Considerations and Strategies for Lead Optimization
¢º ±è¼öÇå ´ëÇ¥ / (ÁÖ)Å¥º£½ºÆ®¹ÙÀÌ¿À
11:55-12:10 Q & A
12:10-13:30 Lunch
Session 2: ¾àµ¿ÇÐÀÇ ÀÌÇØ ¹× ÆÄ¶ó¹ÌÅÍ °³³ä
13:30-14:15
¾àµ¿ÇÐ ÀÌÇØ ¹× ADME Overview
Understanding Pharmacokinetics & Overview of ADME
¢º ±è¼ÒÈñ ±³¼ö / ¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ
14:15-14:30 Q & A
14:30-15:15
ÁÖ¿ä ¾àµ¿ÇÐ ÁÖ¿ä ÆÄ¶ó¸ÞÅÍÀÇ °³³ä
Concept of Main Pharmacokinetic Parameters
¢º ±è¼ÒÈñ ±³¼ö / ¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ
15:15-15:30 Q & A
15:30-15:40 Intermediate Break
Session 3: ½Å¾à°³¹ß ½Ç¹«Àü·«
15:40-16:25
¾à¹° ÀçâÃâ¿¡ À־ÀÇ Æ¯Çã
Patents in Drug Repositioning
¢º ÀåÁ¤¼ö º¯¸®»ç / ƯÇã¹ýÀÎ ÇʾؿÂÁö
16:25-16:40 Q & A
16:40-17:25
½Å¾à Çã°¡½É»ç
MFDS¡¯s New Drug Application Review
¢º ±èÈ£Á¤ °úÀå / ½ÄǰÀǾàǰ¾ÈÀüÆò°¡¿ø ¼øÈ¯½Å°æ°è¾àǰ°ú
17:25-17:40 Q & A
17:40- Closing Remark